BMS-1166 Chemical Properties

Boiling point:

817.5±65.0 °C(Predicted)

Density 

1.42±0.1 g/cm3(Predicted)

storage temp. 

Store at -20°C

solubility 

DMF: 30 mg/ml; DMSO: 30 mg/ml; DMSO:PBS (pH 7.2) (1:2): 0.33 mg/ml

form 

A crystalline solid

pka

2.03±0.40(Predicted)

color 

White to off-white

InChIKey

QBXVXKRWOVBUDB-GRKNLSHJSA-N

SMILES

C(O)(=O)[C@H]1C[C@@H](O)CN1CC1=CC(Cl)=C(OCC2=CC=CC(C3=CC=C4OCCOC4=C3)=C2C)C=C1OCC1=CC=CC(C#N)=C1

BMS-1166 Usage And Synthesis

Uses

BMS-1166 is a potent PD-1/PD-L1 immune checkpoint inhibitor. BMS-1166 induces dimerization of PD-L1 and blocks its interaction with PD-1, with an IC50 of 1.4 nM. BMS-1166 antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation[1][2].

Biological Activity

BMS-1166 is a novel and potent inhibitor of PD-1/PD-L1 interaction with IC50 of 1.4 nM.

in vitro

BMS-1166 had low toxicity to the tested cell lines and prevented the interaction of soluble PD-L1 with PD-1 receptors expressed on the cell surface. It attenuates the inhibitory effect of PD-L1 on T cell receptor-mediated T lymphocyte activation.

target

References

[1] Guzik K, et al. Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1. J Med Chem. 2017 Jul 13;60(13):5857-5867. DOI:10.1021/acs.jmedchem.7b00293
[2] Skalniak L, et al. Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells. Oncotarget. 2017 Aug 7;8(42):72167-72181. DOI:10.18632/oncotarget.20050